Acremonium fusidioides YMF-1 strain and its use for skin improvement

A novel Acremonium fusidioides strain from forest soil addresses the depletion and pollution issues of existing cosmetic ingredients by providing a lysate and culture medium that enhance skin health through specific biological mechanisms, achieving moisturizing, barrier strengthening, regeneration, and anti-inflammatory effects.

KR103044926B1Active Publication Date: 2026-11-10COSMAX INC
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
KR1020230191862
Authority / Receiving Office
KR · KR
Patent Type
Patents
Current Assignee / Owner
Filing Date
2023-12-26
Publication Date
2026-11-10
Estimated Expiration
2043-12-26

AI Technical Summary

Technical Problem

Existing cosmetic ingredients derived from macrobial resources or synthetic compounds face issues of material depletion and environmental pollution, necessitating the development of natural biological resources for skin improvement.

Method used

A novel strain of Acremonium fusidioides, isolated from forest soil, is used to produce a lysate, culture medium, or extract, which are biologically pure and effective in improving skin conditions through mechanisms such as increasing filaggrin and Aquaporin 3 expression, promoting fibroblast migration, and reducing inflammatory cytokines like TNF-α, IL-1β, and IL-6.

Benefits of technology

The Acremonium fusidioides strain demonstrates skin moisturizing, barrier strengthening, regeneration, wound healing, anti-inflammatory, and soothing effects, addressing various skin conditions including inflammatory diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 112023145812583-PAT00001_ABST
    Figure 112023145812583-PAT00001_ABST
Patent Text Reader

Abstract

The present invention relates to the Acremonium fusidioides YMF-1 strain, its lysate, culture medium, extract of the culture medium, and their use for skin improvement. Since the strain possesses skin moisturizing, skin barrier strengthening, skin regeneration, wound healing, anti-inflammatory, and skin soothing effects, it can be usefully employed in cosmetics, pharmaceuticals, food, etc.
Need to check novelty before this filing date? Find Prior Art

Description

Technology Field

[0001] The invention relates to a novel microorganism, its lysate, culture medium, extract of the culture medium, and their use for improving skin. Background Technology

[0002] Most cosmetic ingredients developed to date are macrobial resources or synthetic compounds, which present problems such as material depletion and environmental pollution. Therefore, there is a need to develop cosmetic ingredients derived from natural biological resources to overcome these issues and satisfy the heightened demands of consumers. Historically, soil has served as a source for discovering new substances with biological activity. Biologically active molecules isolated from soil biota are being actively researched for application in fields such as pharmacy, food nutrition, cosmetics, agriculture, and molecular biology. Furthermore, it has been reported that microorganisms in the soil are involved in the production of various physiologically active molecules, and the potential for their medical and industrial applications is increasing.

[0003] Therefore, there is a need to develop soil microbial materials that can be usefully utilized for skin improvement. Prior art literature

[65535] (Patent Document 0001) KR 10-2022-0012097 A The problem to be solved

[0004] One aspect is the novel Acremonium pusidioides ( Acremonium fusidioides It is to provide a strain.

[0005] Another aspect is to provide a lysate, culture medium, or extract of the culture medium of the above-mentioned strain.

[0006] Another aspect provides a method for preparing an Acremonium fusidioides strain culture, comprising the steps of: culturing the strain to obtain a culture medium; and removing the cells from the culture medium and recovering the supernatant.

[0007] Another aspect is Acremonium pusidioides ( Acremonium fusidioides It is to provide a use for the strain, its lysate, culture medium, or extract of the culture medium.

[0008] Another aspect is Acremonium pusidioides ( Acremonium fusidioides The invention provides a composition comprising a strain, its lysate, culture medium, extract of the culture medium, or a mixture thereof.

[0009] Another aspect provides a method for preventing, improving, or treating the condition of an individual, comprising the step of administering an effective amount of the above-mentioned composition to an individual in need thereof. means of solving the problem

[0010] One aspect is Acremonium psisioides ( Acremonium fusidioides Provides a strain.

[0011] The strain mentioned above may be isolated. In this specification, the term "isolated" means that which is not found in nature but is artificially isolated and available for use. The strain mentioned above may be isolated from soil. Specifically, the strain mentioned above may be isolated from forest soil. Forest soil may refer to sediment accumulated in a forest. The strain mentioned above may be a strain isolated by a method of pure isolation culture of colonies cultured by inoculating a soil sample into a malt extract (ME) medium.

[0012] The above Acremonium pusidioides ( Acremonium fusidioides The strain may be the strain deposited under accession number KCCM13417P. The strain is Acremonium fusidioides ( Acremonium fusidioides It could be the YMF-1 strain.

[0013] The above Acremonium pusidioides ( Acremonium fusidioidesThe strain may comprise the 26S rRNA D1 / D2 sequence of SEQ ID NO. 1. In one embodiment, the strain may comprise a 26S rRNA D1 / D2 sequence having sequence identity with SEQ ID NO. 1 of at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99%, at least 99.5%, at least 99.9%, 95% to 100%, 96% to 100%, 97% to 100%, 98% to 100%, 99% to 100%, 99.5% to 100%, or 99.9% to 100%.

[0014] As used herein, the term “sequence identity” refers to the degree of similarity of amino acid residues or bases between sequences after aligning both sequences to match as much as possible in a specific comparison region. Sequence identity can be verified according to methods known in the art. The percentage of sequence identity can be determined using known sequence comparison programs, such as BLASTN (NCBI), CLC Main Workbench (CLC bio), MegAlign™ (DNASTAR Inc).

[0015] The above strain may have skin improvement effects, skin condition improvement effects, skin beauty improvement effects, or preventive, improving, or therapeutic effects for skin diseases. For example, the above strain may have skin moisturizing, skin barrier strengthening, skin regeneration, wound healing, anti-inflammatory, and skin soothing effects. Additionally, the above strain may have preventive, therapeutic, or improving effects for diseases caused by damage to skin barrier function or inflammatory skin diseases.

[0016] In one embodiment, the strain may increase the expression of one or more of filaggrin (FLG) and AQP3 (Aquaporin 3).

[0017] In one embodiment, the strain may promote the migration of fibroblasts.

[0018] In one embodiment, the strain may reduce or inhibit the expression of one or more of TNF-α, IL-1β, and IL-6.

[0019] Another aspect provides a lysate, culture medium, or extract of the culture medium of the above strain.

[0020] The details of the above strain are as described above.

[0021] In this specification, the term "lysate" may be used interchangeably with "lysate" and may refer to a product obtained by lysing the cell walls of a strain by chemical or physical force. The lysate may include the lysate itself, a concentrate thereof, or a freeze-dried product.

[0022] In this specification, the term "culture medium" may be used interchangeably with "culture supernatant," "conditional culture medium," or "conditioning medium," and may refer to the entire medium containing the strain, its metabolites, excess nutrients, etc., obtained by culturing the strain for a certain period in a medium capable of supplying nutrients so that the strain can grow and survive in a test tube. Additionally, the culture medium may refer to a culture medium from which the cells have been removed from a culture medium obtained by culturing the strain. Meanwhile, the liquid from which the cells have been removed from the culture medium is also referred to as the "supernatant." The supernatant may be obtained by taking only the liquid from the upper layer excluding the part that has settled at the bottom after leaving the culture medium undisturbed for a certain period, by removing the cells through filtration, or by centrifuging the culture medium to remove the sediment at the bottom and taking only the liquid at the top.

[0023] The above "bacterial body" refers to the strain of the present invention itself and includes the strain itself isolated and selected from a soil sample, etc., or the strain isolated from a culture medium by culturing the said strain. The said bacterial body can be obtained by centrifuging the culture medium and taking the portion that settles to the bottom layer, or by letting it sit for a certain period of time and removing the liquid from the top, as it sinks to the bottom layer of the culture medium due to gravity.

[0024] The culture medium and culture conditions for culturing the above strain may be appropriately selected or modified and used by a person of ordinary knowledge. For example, the above culture medium may be obtained by culturing the strain in a suitable medium (e.g., PDB (Potato dextrose broth) medium or ME (Malt extract) medium) at a suitable temperature (e.g., either above 10°C or below 40°C) for a certain period of time (e.g., 24 to 168 hours).

[0025] The above culture medium may include the culture medium itself, a concentrate thereof, or a freeze-dried product obtained by culturing the strain. The above culture medium may include the culture supernatant obtained by removing the strain from the culture medium, a concentrate thereof, or a freeze-dried product.

[0026] In one embodiment, the culture supernatant of the strain can be obtained by the step of removing the cells by centrifuging or filtering the strain culture.

[0027] In another embodiment, the concentrate may be obtained by the step of concentrating the strain culture solution itself, or the supernatant obtained after centrifuging or filtering the culture solution.

[0028] In this specification, the term "culture medium extract" means extracted from the culture medium or its concentrate, and may include an extract, a diluted or concentrated extract, a dried product obtained by drying the extract, a modified or purified product thereof, or a fraction obtained by fractionating the same.

[0029] The above strain, its lysate, culture medium, or extract of the culture medium may be biologically pure. The above strain may be obtained by pure culture.

[0030] Another aspect provides a method for preparing an Acremonium fusidioides strain culture solution, comprising the steps of: culturing the strain to obtain a culture solution; and removing the cells from the culture solution and recovering the supernatant.

[0031] The culture medium and culture conditions for culturing the above strain are as described above.

[0032] The removal of the above-mentioned cells may be achieved using known methods such as centrifugation and filtration.

[0033] Another aspect is Acremonium pusidioides ( Acremonium fusidioides ) provides uses for the strain, its lysate, culture medium, or extract of the culture medium. Specifically, Acremonium fusidioides ( Acremonium fusidioides A composition comprising a strain, its lysate, culture medium, extract of the culture medium, or a mixture thereof is provided.

[0034] In the above use or composition, the strain is Acremonium fusidioides according to the above one aspect ( Acremonium fusidioides ) It may be a strain. Therefore, the strain may be an Acremonium fusidioides YMF-1 strain.

[0035] The uses of the above strain may include skin improvement, improvement of skin condition, improvement of skin beauty, or prevention, improvement, or treatment of skin diseases.

[0036] The above skin improvement, skin condition improvement, or skin beauty improvement may be skin moisturization, skin barrier strengthening, skin regeneration, wound healing, anti-inflammatory, or skin soothing.

[0037] The above "skin moisturization" may refer to any action that maintains skin moisture or prevents moisture loss.

[0038] The above "strengthening of the skin barrier" may refer to any action that enhances the function of the skin barrier, which is located on the outermost layer of the skin and prevents the loss of moisture and nutrients.

[0039] The aforementioned "skin regeneration" may refer to any action that replenishes a part of the skin that has been lost or damaged, or promotes the proliferation and migration of skin cells. As the skin regenerates, wrinkle improvement effects may appear.

[0040] "Wound," also referred to as "injury," signifies damage to a living organism. Such damage may be caused by external factors such as physical injury, radiation, irritation by chemical substances, or the proliferation of microorganisms; or by internal factors such as stress, but is not limited thereto. Such wounds may include all types of wounds, such as incisions, stab wounds, lacerations, contusions, lacerations, puncture wounds, and splinters.

[0041] "Wound improvement" can refer to any action that lightens or reduces the severity of wounds on the face or body. "Wound healing" or "wound recovery" can refer to a series of biological reactions that heal a wound.

[0042] The cause of the above skin regeneration, wound improvement, wound healing, or wound recovery is not limited, but may be, for example, due to the migration or proliferation of skin cells.

[0043] The term "anti-inflammatory" above may be used interchangeably with "improvement of inflammation" or "inflammation suppression," and may include, for example, all actions that suppress the expression of inflammatory cytokines.

[0044] The term "anti-allergic" above may be used interchangeably with "allergy improvement" or "allergy suppression," and may include, for example, any action of removing or suppressing allergens (antigens that cause allergic diseases) or alleviating allergic reactions induced by allergens.

[0045] The term "skin soothing" refers to any action that calms and stabilizes the sensation of heat or pain in irritated skin. The aforementioned skin soothing may include calming skin that has become sensitized by inflammation or allergies.

[0046] The above "skin disease" may be a disease caused by damage to the skin barrier function, a skin wound, a skin scar, an inflammatory skin disease, or an allergic skin disease.

[0047] The aforementioned impairment of skin barrier function may refer to any changes that appear on the skin resulting from a decline or damage to the skin barrier function. For example, it may include increased skin wrinkles, dryness, dermatitis, atopic dermatitis, allergic dermatitis, acne, etc.

[0048] The above-mentioned inflammatory skin disease may be any one selected from the group consisting of skin wounds, dermatitis, atopic dermatitis, pruritus, eczematous skin disease, dry eczema, erythema, urticaria, psoriasis, drug rash, and acne.

[0049] The above skin allergic diseases may include atopic dermatitis, allergic dermatitis, urticaria, pruritus, rash, etc.

[0050] The term "prevention" includes suppressing the occurrence of disease. The term "treatment" includes suppressing, alleviating, or eliminating the progression of disease. The term "improvement" may mean any action that at least reduces parameters related to the alleviation or treatment of a condition, such as the severity of symptoms.

[0051] In one embodiment, the strain, its lysate, culture medium, or extract of the culture medium can increase the expression of one or more of HAS3 and AQP3. Accordingly, the strain, its lysate, culture medium, or extract of the culture medium can exhibit a skin moisturizing or skin barrier strengthening effect.

[0052] In one embodiment, the strain, its lysate, culture medium, or extract of the culture medium can promote the migration of fibroblasts. Accordingly, the strain, its lysate, culture medium, or extract of the culture medium can exhibit a skin regeneration or wound healing effect.

[0053] In one embodiment, the strain, its lysate, culture medium, or extract of the culture medium may reduce or inhibit the expression of one or more of TNF-α, IL-1β, and IL-6. Accordingly, the strain, its lysate, culture medium, or extract of the culture medium may exhibit anti-inflammatory, skin soothing, preventive, improving, or therapeutic effects of inflammatory skin diseases.

[0054] The above strain can be used together with other strains having skin-improving effects, such as strains belonging to the genus Acremonium, to produce a synergistic effect.

[0055] The above composition may include the strain, its lysate, culture medium, extract of the culture medium, or a mixture thereof as an active ingredient.

[0056] The above "included as an active ingredient" means that the strain of this specification, its lysate, culture medium, or extract of the culture medium is added to an extent capable of producing the effects mentioned in this specification, and includes formulation in various forms by adding various components as auxiliary ingredients for drug delivery and stabilization, etc.

[0057] The above strain, its lysate, culture medium, or extract of the culture medium is present in an amount of 0.0001 wt% to 99.9999 wt% based on the total weight of the composition, for example, 0.001 wt% to 80 wt%, 0.01 wt% to 60 wt%, 0.01 wt% to 40 wt%, 0.01 wt% to 30 wt%, 0.01 wt% to 20 wt%, 0.01 wt% to 10 wt%, 0.01 wt% to 5 wt%, 0.05 wt% to 60 wt%, 0.05 wt% to 40 wt%, 0.05 wt% to 30 wt%, 0.05 wt% to 20 wt%, 0.05 wt% to 10 wt%, 0.05 wt% to 5 wt%, 0.1 wt% to 60 wt%, 0.1 wt%, based on the total weight of the composition. It may be included in an amount of up to 40% by weight, 0.1% by weight to 30% by weight, 0.1% by weight to 20% by weight, 0.1% by weight to 10% by weight, or 0.1% by weight to 5% by weight, but is not particularly limited thereto. The content of the active ingredient may be selected as an appropriate content that can be formulated within a content range sufficient to produce the effects mentioned in this specification by a person skilled in the art.

[0058] The above composition may be in a liquid state or a dry state. In one embodiment, the composition may be in the form of a dry powder.

[0059] The drying method for preparing the above composition in a dry state may use methods generally used in the art and is not particularly limited. Non-limiting examples of the above drying method include air drying, natural drying, spray drying, freeze-drying, etc. These methods may be used alone or at least two methods may be used together.

[0060] The above composition may include an effective amount of an additive sufficient to reduce the deterioration of the strain, its lysate, culture medium, or extract of the culture medium. The additive may be, for example, a binder, but is not limited thereto.

[0061] The above composition may further comprise a carrier that is cosmetically, pharmaceutically, or food-grade acceptable. The above composition may be formulated with the carrier and provided as a cosmetic, pharmaceutical, food additive, etc.

[0063] The above composition may be a cosmetic composition.

[0064] The above cosmetic composition may additionally include ingredients commonly used in cosmetic compositions, functional additives, etc., in addition to the active ingredients disclosed in this specification, and may include, for example, conventional auxiliary agents such as antioxidants, stabilizers, solubilizers, surfactants, dispersants, emulsifiers, preservatives, vitamins, pigments, fragrances, etc., and carriers.

[0065] The above cosmetic composition is not specifically limited to a particular formulation, and the formulation can be appropriately selected according to the purpose. The above cosmetic composition may have, for example, a solubilized formulation, an emulsified formulation, or a dispersed formulation. The above cosmetic composition may have, for example, a cosmetic formulation of a lotion, cream, essence, cleansing foam, cleansing water, pack, ampoule, body lotion, body oil, body gel, shampoo, hair conditioner, hair gel, foundation, lipstick, mascara, makeup base, or a skin-adhesive type (e.g., a mask pack).

[0066] In addition, the above composition may be a composition for external use on the skin.

[0067] The above-mentioned topical preparation may be a cream, gel, ointment, skin emulsifier, skin suspension, transdermal patch, drug-containing bandage, lotion, or a combination thereof. The above-mentioned topical preparation may be appropriately formulated as needed with ingredients commonly used in topical preparations for the skin, such as cosmetics or pharmaceuticals, for example, aqueous ingredients, oily ingredients, powder ingredients, alcohols, moisturizers, thickeners, UV absorbers, whitening agents, preservatives, antioxidants, surfactants, fragrances, colorants, various skin nutrients, metal ion chelators, sugars, or combinations thereof.

[0068] The above composition may be a pharmaceutical composition.

[0069] The above pharmaceutical composition may additionally comprise a pharmaceutically acceptable diluent or carrier. The diluent may be lactose, corn starch, soybean oil, microcrystalline cellulose, mannitol, or a combination thereof. The carrier may be an excipient, a disintegrant, a binder, a lubricant, or a combination thereof. The excipient may be microcrystalline cellulose, lactose, low-substituted hydroxycellulose, or a combination thereof. The disintegrant may be calcium carboxymethylcellulose, sodium starch glycolate, calcium anhydrous phosphate, or a combination thereof. The binder may be polyvinylpyrrolidone, low-substituted hydroxypropylcellulose, hydroxypropylcellulose, or a combination thereof. The lubricant may be magnesium stearate, silicon dioxide, talc, or a combination thereof.

[0070] The above pharmaceutical composition may be formulated into an oral or parenteral administration formulation. Oral administration formulations may be granules, powders, liquids, tablets, capsules, dry syrups, etc. Parenteral administration formulations may be injections, ointments, etc.

[0071] The above composition may be a food composition. The above composition may be a health functional food composition. In this case, it may be formulated into a conventional health functional food formulation known in the relevant technical field.

[0072] The above food composition may use the strain, its lysate, culture medium, or extract of the culture medium alone, or in combination with other foods or food ingredients, and may be used appropriately according to conventional methods. The amount of the mixture of active ingredients may be appropriately determined according to the purpose of use (prevention, health, or therapeutic treatment). There are no special restrictions on the types of the above health functional foods. Among the types of health functional foods, the beverage composition may contain various flavoring agents or natural carbohydrates, etc., as additional ingredients, just like ordinary beverages. The above natural carbohydrates are monosaccharides such as glucose and fructose; disaccharides such as maltose and sucrose; polysaccharides such as dextrin and cyclodextrin; and sugar alcohols such as xylitol, sorbitol, and erythritol. As sweeteners, natural sweeteners such as taumatin and stevia extract, or synthetic sweeteners such as saccharin and aspartame may be used. The above food composition may also contain nutritional supplements, vitamins, electrolytes, flavoring agents, coloring agents, pectic acid and its salts, alginic acid and its salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohol, carbonating agents used in carbonated beverages, or combinations thereof. The above food composition may also contain fruit pulp for the production of natural fruit juice, fruit juice beverages, vegetable beverages, or combinations thereof.

[0073] Another aspect provides a method for preventing, improving, or treating the condition of an individual, comprising the step of administering an effective amount of the above-described composition to an individual in need thereof.

[0074] The condition of the above-mentioned entity may be a condition related to the skin, and specifically, it may be a disease caused by damage to the skin barrier function, a skin wound, a skin scar, an inflammatory skin disease, or an allergic skin disease.

[0075] The above skin includes all skin parts of the body, including the face, hands, arms, legs, feet, chest, abdomen, back, buttocks, and scalp.

[0076] The term "effective amount" refers to an amount effective enough to produce the effect mentioned above.

[0077] In this specification, the terms “administering,” “introducing,” and “implanting” are used interchangeably and may mean the placement of a composition according to one embodiment into an individual by a method or route resulting in at least partial localization of the composition according to one embodiment to a desired site.

[0078] Administration may be carried out by methods known in the art. Methods of administration, such as the route of administration and the frequency of administration, may be appropriately selected by a person skilled in the art. Administration may be administered directly to an individual by any means, for example, via routes such as intravenous, intramuscular, oral, transdermal, mucosal, intranasal, intratracheal, or subcutaneous administration. The administration may be systemic or local. The administration may include application to the skin.

[0079] The above-mentioned individual may be a mammal, for example, a human, cattle, horses, pigs, dogs, sheep, goats, or cats. The above-mentioned individual may be an individual requiring improvement of skin condition, for example, skin moisturization, skin barrier strengthening, skin regeneration, wound healing, skin soothing, anti-inflammatory, or anti-allergic effects.

[0080] The above administration may be of administering the composition according to one embodiment in an amount of 0.1 mg to 1,000 mg per individual per day, for example, 0.1 mg to 500 mg, 0.1 mg to 100 mg, 0.1 mg to 50 mg, 0.1 mg to 25 mg, 1 mg to 1,000 mg, 1 mg to 500 mg, 1 mg to 100 mg, 1 mg to 50 mg, 1 mg to 25 mg, 5 mg to 1,000 mg, 5 mg to 500 mg, 5 mg to 100 mg, 5 mg to 50 mg, 5 mg to 25 mg, 10 mg to 1,000 mg, 10 mg to 500 mg, 10 mg to 100 mg, 10 mg to 50 mg, or 10 mg to 25 mg. However, the dosage may vary depending on factors such as the formulation method, method of administration, patient's age, body weight, gender, pathological condition, food, time of administration, route of administration, excretion rate, and response sensitivity, and a person skilled in the art may appropriately adjust the dosage by considering these factors. The frequency of administration may be once a day or two or more times within the range of clinically acceptable side effects. Regarding the administration site, it may be administered at one or two or more sites, and the total duration of administration may range from 1 to 30 days per treatment, administered daily or at intervals of 2 to 5 days. If necessary, the same treatment may be repeated after the appropriate time. For animals other than humans, the dosage may be the same as that for humans per kg, or an amount calculated by converting the above dosage based on, for example, the ratio of organ (e.g., heart) volumes between the target animal and humans (e.g., average value).

[0081] Another aspect provides the use of the strain, its lysate, culture medium, or extract of the culture medium for use in preparing a composition for improving skin.

[0082] Another aspect provides the use of the strain, its lysate, culture medium, or extract of the culture medium for use in manufacturing a skin regenerative agent, a wound healing agent, or a agent for the prevention or treatment of inflammatory skin diseases.

[0083] Redundant content is omitted out of consideration for the complexity of this specification, and terms not otherwise defined in this specification have the meanings commonly used in the technical field to which this invention belongs. Effects of the invention

[0084] According to a novel strain of Acremonium fusidioides based on one aspect, it has skin-improving effects such as skin moisturization, skin barrier strengthening, skin regeneration, wound healing, anti-inflammatory effects, prevention, improvement or treatment of inflammatory skin diseases, and skin soothing, and can be usefully applied in cosmetics, pharmaceuticals, food, etc. Brief explanation of the drawing

[0085] Figure 1 is a graph showing the relative expression levels of FLG. Figure 2 is a graph showing the relative expression levels of AQP3. Figure 3 is a graph showing the change in cell saturation (relative wound density) in culture dishes as fibroblasts migrate after cell wounds are healed in a medium containing YMF-1 strain culture and a medium not containing it (-). Figure 4 is a graph showing the relative expression levels of TNF-α. Figure 5 is a graph showing the relative expression levels of IL-1β. Figure 6 is a graph showing the relative expression levels of IL-6. Specific details for implementing the invention

[0086] The following examples will be explained in more detail. However, these examples are intended to illustrate one or more specific examples, and the scope of the present invention is not limited to these examples.

[0087] [Example]

[0088] Example 1: Isolation and Identification of Strains

[0089] Novel Acremonium fusidioides from soil ( Acremonium fusidioides ) strains were isolated and identified.

[0090] Specifically, sediment was collected from the soil of Gwanggyosan Mountain in Suji-gu, Yongin-si, Gyeonggi-do, South Korea, at a depth of 10 cm from the surface, and placed in a sterile polyethylene container. The sediment was sieved using a sterile 2-mm sieve, and 1 g of the filtered sediment was added to 10 mL of sterile distilled water (DW) and vortexed to prepare a suspension. The sediment suspension was serially diluted at a ratio of 1 g : 1000 mL. 3 mL of the diluted suspension was added to 47 mL of a medium consisting of 2% malt extract, 3.59% artificial sea salt (Instant Ocean, Aquarium Systems, Mentor, OH, USA), and 0.01% streptomycin sulfate (Sigma-Aldrich, St. Louis, MO, USA). 150 μL of the inoculated medium was added to each well of a sterile 96-well plate and cultured at room temperature for 2-4 weeks until mycelia were visible to the naked eye. Afterward, each fungal colony was transferred to a 2% malt extract agar plate containing 0.01% streptomycin sulfate, cultured at room temperature for one week, and purified to obtain a single strain.

[0091] Genomic DNA was extracted from fungal cultures using the AccuPrep® Genomic DNA Extraction Kit (Bioneer, Seoul, Republic of Korea), and PCR amplification of the D1 / D2 region was performed using NL1-NL4 primers [NL1 (5'-GCATATCAATAAGCGGAGGAAAAG-3'; SEQ ID NO. 2) and NL4 (5'-GGTCCGTGTTTCAAGACGG-3'; SEQ ID NO. 3). PCR amplification was carried out for 35 cycles of 95°C for 30 seconds, 55°C for 30 seconds, and 72°C for 2 minutes, followed by treatment at 72°C for 7 minutes and storage at 4°C. The PCR products were purified using the AccuPrep® PCR Purification Kit (Bioneer, Seoul, Korea), and the DNA sequences were analyzed using a 3730xl DNA Analyzer (Life Technology, Carlsbad, CA, USA).

[0092] Using the BLAST program provided on the website of the National Center for Biotechnology Information (NCBI), the nucleotide sequences of the D1 / D2 regions of the analyzed 26S rRNA gene were compared with other strains registered in NCBI. Among them, the novel microorganism Acremonium fusidioides, which showed 100.00% homology ( Acremonium fusidioides A strain (hereinafter referred to as "YMF-1") was selected.

[0093] The selected YMF-1 strain was deposited with the Korean Culture Center of Microorganisms (KCCM) on November 13, 2023, and was assigned accession number KCCM13417P. The YMF-1 strain has the 26S rRNA D1 / D2 region sequence of SEQ ID No. 1 (complementary DNA).

[0094] Example 2: Preparation of strain culture solution

[0095] Acremonium pusidioides Acremonium fusidioides A culture solution of the YMF-1 strain was prepared.

[0096] Specifically, the YMF-1 strain isolated in Example 1 above was cultured in PDB (Potato dextrose broth) medium at 25°C for 7 days. After culture, the culture medium obtained was centrifuged to remove the cells, and the supernatant was recovered. The recovered supernatant was used as the YMF-1 strain culture medium in the following experimental examples.

[0097] [Experimental Example]

[0098] Experimental Example 1: Evaluation of skin moisturizing and skin barrier strengthening efficacy

[0099] To evaluate the skin moisturizing and skin barrier strengthening activities of the above YMF-1 strain culture, the expression levels of FLG and AQP3 were analyzed.

[0100] FLG (Flaggrin) and AQP3 (Aquaporin 3) are factors related to skin moisturization and strengthening the skin barrier.

[0101] 1-1: Cell Culture and Sample Processing

[0102] HaCaT human keratinocyte cells were cultured in DMEM medium (Dulbecco's modified Eagle's Medium, Gibco 1210-0038) containing 10% fetal bovine serum, and all cultures were performed in a 37°C, 5% CO2 incubator. The medium was changed every 3–4 days, and subculture was performed when the cells proliferated excessively. Subsequently, the cells were cultured at a rate of 5 x 10⁶ 5 After dispensing into cells / wells and culturing for 24 hours, 0.1% (w / w) of the YMF-1 strain culture medium was added, followed by additional culturing for 24 hours.

[0103] 1-2: Analysis of Gene Expression Levels

[0104] The above culture was recovered, RNA was isolated using Trizol (RNA iso, DAKARA, Japan), and then quantified at 260 nm using Nanodrop. cDNA was synthesized in an amplifier using 2 μg of RNA (C1000 Thermal Cycler, Bio-Rad, USA). Using the synthesized cDNA as a template, real-time polymerase chain reaction was performed on a real-time PCR machine (Step One Plus, Applied Biosystems, USA) by adding CyberGreen (SYBR Green supermix, Applied Biosystems, USA) and primers for the target gene (FLG or AQP3). The gene expression level was finally analyzed after correction for the β-actin gene.

[0105] 1-3: Result

[0106] Figure 1 is a graph showing the relative expression levels of FLG.

[0107] Figure 2 is a graph showing the relative expression levels of AQP3.

[0108] As a result, as shown in Figures 1 and 2, it was confirmed that Example 2 (strain culture) significantly increased the expression of FLG and AQP3 compared to the untreated control group.

[0109] Therefore, it was confirmed that the YMF-1 strain has skin moisturizing and skin barrier strengthening effects.

[0110] Experimental Example 2: Evaluation of Skin Regeneration Efficacy

[0111] To evaluate the skin regeneration efficacy of the above YMF-1 strain culture, fibroblast migration ability was analyzed.

[0112] 2-1: Method for Analyzing Fibroblast Migration Ability

[0113] Human dermal fibroblast (Hs68) cell line in 3x10⁻⁶ 5After dispensing into wells, the cells were cultured in an incubator at 37°C with 5% CO2 for 24 hours to reach a 100% confluent state. Subsequently, a cell scraper was used to scrape the center of the cultured cells to create a wound. The medium was then replaced with a medium containing 1% (w / w) of the YMF-1 strain culture solution and a medium without it, followed by an additional 24 hours of culture. After 24 hours, the extent of recovery of the arbitrarily created wounds on the cells was photographed using a fluorescence microscope in the cases containing and without the strain culture solution.

[0114] 2-2: Result

[0115] Figure 3 is a graph showing the change in cell saturation (relative wound density) in culture dishes as fibroblasts migrate after cell wounds are healed in a medium containing YMF-1 strain culture and a medium not containing it (-).

[0116] As a result, as shown in Figure 3, it was found that when cultured in a medium containing Example 2 (strain culture), the migration of fibroblasts to the damaged site was significantly increased compared to the control group not containing Example 2.

[0117] Therefore, it was confirmed that the YMF-1 strain has skin regeneration promoting and wound healing effects.

[0118] Experimental Example 3: Evaluation of Anti-inflammatory and Skin Soothing Efficacy

[0119] To evaluate the anti-inflammatory and skin-soothing effects of the above YMF-1 strain culture, the expression levels of TNF-α, IL-1β, and IL-6 were analyzed.

[0120] TNF-α (tumor necrosis factor-α), IL-1β (interleukin-1β), and IL-6 (interleukin-6) are inflammatory cytokines.

[0121] 3-1: Cell Culture and Sample Processing

[0122] Hs68 human fibroblast cells were cultured in DMEM medium (Dulbecco's modified Eagle's Medium, Gibco 1210-0038) containing 10% fetal bovin serum, and all cultures were performed in a 37°C, 5% CO2 incubator. The medium was changed every 3–4 days, and subculture was performed when the cells proliferated excessively. Subsequently, the cells were cultured at a rate of 5 x 10⁶ 5 Cells were dispensed into wells and, after 24 hours of culture, washed with phosphate-buffered saline (PBS). Cells were dispensed into each well containing DMEM medium free of FBS, and inflammation was induced in the keratinocyte cell line by adding 10 μg / mL of Poly I:C. Next, 0.1% (w / w) or 1% (w / w) of the YMF-1 strain culture medium was added, followed by an additional 4 hours of culture. 1 μM of dexamethasone was used as a positive control.

[0123] 3-2: Analysis of Gene Expression Levels

[0124] Gene expression levels were analyzed using the same method as in Experimental Examples 1-2 above, except that primers for TNF-α, IL-1β, or IL-6 were used.

[0125] 3-3: Result

[0126] Figure 4 is a graph showing the relative expression levels of TNF-α.

[0127] Figure 5 is a graph showing the relative expression levels of IL-1β.

[0128] Figure 6 is a graph showing the relative expression levels of IL-6.

[0129] As a result, as shown in Figures 4 to 6, it was confirmed that Example 2 (strain culture) significantly reduced the expression of TNF-α, IL-1β, and IL-6 compared to the untreated control group.

[0130] Therefore, it was confirmed that the YMF-1 strain possesses anti-inflammatory effects, preventive, improving, or therapeutic effects on inflammatory skin diseases, and skin soothing effects.

[0131] In summary, it was confirmed that the Acremonium fusidioides YMF-1 strain increases the expression of FLG and AQP3; promotes fibroblast migration; and inhibits the expression of TNF-α, IL-1β, and IL-6.

[0132] Therefore, it was found that the YMF-1 strain possesses skin moisturizing, skin barrier strengthening, skin regeneration, wound healing, anti-inflammatory, prevention, improvement or treatment of inflammatory skin diseases, and skin soothing effects.

[0133] Depository Name: Korean Culture Collection Center (KCCM) Trustee Number: KCCM13417P Date of Deposit: 2023-11-13

Claims

Claim 1 Acremonium pusidioides deposited under accession number KCCM13417P ( Acremonium fusidioides ) YMF-1 strain. Claim 2 Claim 1, wherein the strain comprises the 26S rRNA D1 / D2 sequence of SEQ ID NO.

1. Claim 3 The strain of claim 1, wherein the strain increases the expression of one or more of filaggrin (FLG) and AQP3 (Aquaporin 3); promotes the migration of fibroblasts; or decreases or inhibits the expression of one or more of TNF-α, IL-1β, and IL-6. Claim 4 Culture solution of the strain of claim 1. Claim 5 Acremonium pusidioides Acremonium fusidioides A cosmetic composition comprising a strain, its lysate, culture medium, extract of the culture medium, or a mixture thereof. Claim 6 A cosmetic composition according to claim 5, which is for improving skin. Claim 7 A cosmetic composition according to claim 6, wherein the skin improvement is skin moisturization, skin barrier strengthening, skin regeneration, anti-inflammatory, or skin soothing. Claim 8 Acremonium pusidioides Acremonium fusidioides A topical skin composition comprising a strain, its lysate, culture medium, extract of the culture medium, or a mixture thereof. Claim 9 Acremonium pusidioides Acremonium fusidioides A pharmaceutical composition for skin regeneration, wound healing, or prevention or treatment of inflammatory skin diseases, comprising a strain, its lysate, culture medium, extract of the culture medium, or a mixture thereof. Claim 10 Acremonium pusidioides Acremonium fusidioides A food composition comprising a strain, its lysate, culture medium, extract of the culture medium, or a mixture thereof.

Citation Information

Patent Citations

  • A cosmetic composition comprising oil extract of Fucidium coccineum cells

    KR1020230160102A

  • Cosmetic composition comprising supercritical extract of fusidium coccineum strain cells

    WO2023224274A1

  • New cyclic pentadepsipeptide and composition for wound healing and regeneration comprising new cyclic pentadepsipeptide as an effective ingredient

    KR1020220012097A